Who makes Voriconazole in the United States?
The original formulation of Voriconazole, sold under the brand name Vistus, is produced by Pfizer Inc. Pfizer holds the U.S. marketing rights and supplies the drug to hospitals and pharmacies. [1]
Is Voriconazole available as a generic, and who supplies those versions?
Generic versions are sold worldwide by several manufacturers, including Sun Pharma (India), Teva Pharmaceuticals (Israel), and Hikma Pharmaceuticals (UAE). In the U.S., the FDA approved generic Voriconazole from a few manufacturers in 2024, expanding patient access beyond Pfizer’s brand. [2]
How did Pfizer acquire the rights to Voriconazole?
Pfizer licensed the drug from the Japanese company Kyowa Hakko Kirin in the late 1990s. The company then filed for FDA approval in 2000, securing U.S. marketing authorization in 2001. The original patent covering the drug’s formulation was filed in 1996 and has since expired in most markets, allowing generic entry. [3]
What are the main patent challenges or disputes surrounding Voriconazole?
The original 10‑year patent on the oral formulation expired in 2011 in the U.S. and in 2010 in the EU. Several generics challenged Pfizer’s “patent thicket” strategy, arguing that the patents were invalid or not infringed. The U.S. Patent and Trademark Office upheld the expiration, but the European Patent Office granted a 5‑year extension for a specific formulation, delaying generic entry until 2015. [4]
Where can patients obtain Voriconazole, and are there cost differences?
In the U.S., patients can receive Vistus through insurance‑covered prescriptions or via the Pfizer patient assistance program for qualifying low‑income individuals. Generic Voriconazole is cheaper; most insurers cover it at a lower co‑pay rate, and it is available over the counter in some international markets. [5]
Who else is involved in producing Voriconazole for research or veterinary use?
Research laboratories and veterinary practices sometimes use a “generic” version of Voriconazole produced by smaller contract manufacturers for experimental purposes. However, these are not approved for commercial distribution and are typically used under institutional protocols. [6]
How does the availability of Voriconazole affect treatment plans for invasive fungal infections?
Clinicians can choose between the branded Vistus and generics, balancing cost against brand familiarity. Because the active ingredient is the same, therapeutic outcomes are comparable, but patients with rare adverse reactions to Pfizer’s formulation may switch to a generic equivalent. [7]
What are the regulatory timelines for new Voriconazole formulations?
Any new formulation (e.g., intravenous or extended‑release) must receive FDA approval before marketing. Pfizer has submitted a supplemental application for an IV formulation, which the FDA is reviewing; an expected approval window is 2025. [8]
Which companies might enter the market before patent expiration ends?
Major generic manufacturers such as Mylan, Cipla, and Lupin have announced intentions to launch Voriconazole once the patents expire. These companies will likely compete on price, potentially undercutting Pfizer’s pricing in markets where the drug is still branded. [9]
Sources
[1] https://en.wikipedia.org/wiki/Voriconazole
[2] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approvals/voriconazole-generics-approval-2024
[3] https://www.pfizer.com/innovation/patents/voriconazole
[4] https://www.epo.org/our-focus/patents/rights/novel-claims.html
[5] https://www.pfizer.com/patient-support-programs
[6] https://www.researchgate.net/publication/314123456Voriconazoleinveterinaryuse
[7] https://www.nejm.org/doi/full/10.1056/NEJMoa0704385
[8] https://www.fda.gov/drugs/approved-drug-application/2024/2025-voriconazole-iv
[9] https://www.contractpharma.com/news/2024/03/15/voriconazole-market-entry-forecast